These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prognostic significance of metabolic parameters measured by 18F-FDG PET/CT in limited-stage small-cell lung carcinoma.
    Author: Chang H, Lee SJ, Lim J, Lee JS, Kim YJ, Lee WW.
    Journal: J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157.
    Abstract:
    PURPOSE: Metabolic parameters measured by [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) are important prognostic factors in several types of cancers. We evaluated the predictive value of tumor metabolic parameters measured by 18F-FDG PET/CT in limited-disease small-cell lung cancer (LD-SCLC). METHODS: This retrospective study included 30 LD-SCLC patients who underwent standard chemotherapy after radiotherapy with 18F-FDG PET/CT. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and blood glucose-corrected values were used to evaluate metabolic parameters in primary tumors. RESULTS: For the median follow-up of 41.1 months, median overall survival (OS) was 75.0 months [95% confidence interval (CI) 20.9-129.1 months], and median progression-free survival (PFS) was 9.5 months (95% CI 6.8-12.1 months). Two-year OS was 78.6%, and PFS was 32.7%. OS analysis indicated that MTV and TLG were significant predictors of OS following standard treatment. High glucose-corrected SUVmax (glu-SUVmax) was related to shorter median PFS. On multivariate analysis, MTV was an independent factor of OS, and glu-SUVmax was significantly related to PFS. CONCLUSIONS: MTV and glu-SUVmax measured on pretreatment 18F-FDG PET/CT were independent prognostic factors for LD-SCLC patients after chemoradiotherapy with curative intent. These metabolic markers need validation in larger prospective studies but may be useful in the clinical care of LD-SCLC patients.
    [Abstract] [Full Text] [Related] [New Search]